Hepatology

Article	Citations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	1599
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	1394
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	1273
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	789
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	512
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	437
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	358
Efficacy and safety of infliximab in patients with autoimmune hepatitis	286
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	263
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	224
Retracted	207
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	203
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	198
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model	190
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	178
Cover Image	171
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	166
Late-Breaking Abstracts	161
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	160
Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients	156
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	156
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	155
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	151
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	151
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	146

Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	136
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	130
REPLY:	125
Reply	124
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	124
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	123
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	122
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	119
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	118
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	118
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	117
Obituary for Roberto J. Groszmann—The Father of Portal Hypertension	117
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	116
Access to technology to support telehealth in areas without specialty care for liver disease	113
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction-associated steatosis	111
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	110
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	106
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	105
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	105
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	105
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate–Activated Protein Kinase Signaling Pathway	104
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	102
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	101
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	100
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression	99
Regulatory role and translational potential of CCL11 in liver fibrosis	98
	97
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	97
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	97
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	94
	93
Instructions to Authors	91
Letter to the editor	89
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	88
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	87
Erratum	87
Healthy peribiliary glands are necessary for successful liver transplantation	87
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	86
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	83
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	82
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?	82
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty	80
Letter to the Editor: Overlooking the important factor: Hypoxia	80
Reply	80
Extracellular Signal‐Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells	79
MRI‐Based Iron Phenotyping and Patient Selection for Next‐Generation Sequencing of Non–Homeostatic Iron Regulator Hemochromatosis Genes	79
REPLY:	78
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	77
In vivo imaging of calcium dynamics in zebrafish hepatocytes	77
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	76

Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	76
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	76
Letter to the Editor	76
Much more needed in natural history of Alagille syndrome	75
Hepatology Highlights	75
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer	73
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	72
To Be or Not to Be	72
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease	72
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers	71
Magnetic resonance elastography for prediction of long‐term progression and outcome in chronic liver disease: A retrospective study	71
With Alcohol as the Fuel, COVID Is the Match	71
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement	71
Dedifferentiation‐associated inflammatory factors of long‐term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment	70
Endpoints and New Options for Treatment of Chronic Hepatitis D	69
Fontan‐associated liver disease	68
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	68
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	67
The international quest for the imaging diagnosis of liver cancer	67
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	67
Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia	67
Therapeutic manipulation of the microbiome in liver disease	66
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	66
Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?	65
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	64
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis	64
The digital determinants of liver disease	64
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH	63
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	63
Genes that fit just right: Unzipping the genome of fatty liver disease	63
Outcomes of pregnancy in autoimmune hepatitis: A population‐based study	62
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	62
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	62
NAFLD‐related hepatocellular carcinoma: The growing challenge	61
Metabolic dysfunction-associated steatotic liver disease and the heart	61
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	61
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome	60
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	60
Immunobiology of primary sclerosing cholangitis	60
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	59
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature	59
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	59
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study	58
A strategy of vascular‐targeted therapy for liver fibrosis	58
The Addition of C‐Reactive Protein and von Willebrand Factor to Model for End‐Stage Liver Disease‐Sodium Improves Prediction of Waitlist Mortality	58
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness	58
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via non-canonical phosphorylation	58
A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease	57
Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Sh	57
Serum amyloid A1-Induced intrahepatic regulatory T cell dysfunction drives autoimmune hepatitis progression	57
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent	57
Enoxacin Up‐Regulates MicroRNA Biogenesis and Down‐Regulates Cytotoxic CD8 T‐Cell Function in Autoimmune Cholangitis	56
The clot and the complicated consult	56
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis	56
Letter to the editor: RECAM for the diagnosis of DILI—Is it time to incorporate additional pharmacological criteria?	55
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block	55
Reply	55
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles	55
Reply	54
Early detection of primary liver cancer using plasma cell‐free DNA fragmentomics: Do all the pieces come together?	54
REPLY:	54
Hepatology Highlights	54
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study	53
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia	53
Manuscript best practices: Takeaways from a community conversation	53
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease	53
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy	52
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease	52
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis	51
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling	51
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC	51
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”	51
In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood	51
Reply	51
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	51
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study	51
Reply	50
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	50
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	50
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States	49

Letter to the editor: Considerations on the use of the liver transplant comorbidity index (LTCI)	49
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort	49
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy	49
Letter to the Editor: Recognizing Significant Role of Neoadjuvant Radiotherapy for HCC With Vascular Invasion	49
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases	49
Reply	49
Letter to editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function	48
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution	48
E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants	48
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase	48
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol	48
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease	47
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study	47
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation	47
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma	47
Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS	47
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies	47
Future directions in acute liver failure	46
Pathway to global elimination of hepatitis B: HBV cure is just the first step	46
Oral Abstracts	46
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features	46
Table of contents	45
Cover Image	45
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices	45
Letter to the editor: High rate of clinical and immunological response in patients with HCV‐associated cryoglobulinemia	45
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!	45
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	45
Table of contents	45
Letter to the editor: Relevance of population‐based cutoffs to define frailty in clinical studies	44
Reply	44
Masthead	44
Masthead	43
Cover Image	43
Erratum for Ren, H et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of hepatocyte nuclear factor 4α	43
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?	43
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial	42
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease	42
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis	42
Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma	42
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study	42
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon	42
Corticosteroids for high‐grade immune checkpoint inhibitor–mediated hepatitis: Is less more?	42
Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease	42
Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFβ Pathway Activation	42
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations	41
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency	41
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs	41
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions	40
Letter to the editor: HuR in liver homeostasis	40
Letter to the Editor: Liver Stiffness by Transient Elastography to Detect Porto‐sinusoidal Vascular Liver Disease	40
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC	40
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study	40
Imaging for better responses to immunotherapy in hepatocellular carcinoma	40
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis	40
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors	40
Tripartite motif‐containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen‐activated protein kinase kinase kinase 7	40
Reply	40
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?	39
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease	39
Presenting the new incoming editorial team for hepatology: Team members and perspectives	39
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations	39
Letter to the Editor: More questions than answers—Response to the POP-NEXT project	39
Predicting liver outcomes with biomarker monitoring in MASLD	38
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west	38
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys	38
Myofibroblast‐Specific Msi2 Knockout Inhibits HCC Progression in a Mouse Model	38
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality	38
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury	38
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	38
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD	38
Telehealth interventions in patients with chronic liver diseases: A systematic review	38
Intrahepatic cholangiocarcinoma PANoptosidy	37
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study	37
Fructose‐1,6‐Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and Lipogenesis	37
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis	37
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges	37
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets	37
Dissecting liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure	37
Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma	37
Tertiary lymphoid structures in hepatocellular carcinoma: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	37
Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway	37
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI	36
Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis	36
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma	36
A global action agenda for turning the tide on fatty liver disease	36
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC	36
Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes	36
Hepatocyte‐derived MASP1‐enriched small extracellular vesicles activate HSCs to promote liver fibrosis	36
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population	36
Metabotropic Glutamate Receptor 5 in Natural Killer Cells Attenuates Liver Fibrosis by Exerting Cytotoxicity to Activated Stellate Cells	36
Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV‐specific T‐cell response and homing	36
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab	36
Category Index	35
Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding	35
Letter to the Editor: Use of HBV RNA and to predict change in serological status and disease activity in CHB	35